ABOUT THIS FUND
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
PRICE
$67.09 ▼ DOWN 3.48% (−$2.42)HOLDINGS
TOP 20 OF 103 · 49.71% OF THE FUNDRANK STOCK WEIGHT SHARES VALUE
